A phase II clinical trial of ZD1839 ( gefitinib) in combination with docetaxel as first-line treatment in patients with advanced breast cancer

被引：0
|
作者：
Dennison, S. K.
Jacobs, S. A.
Wilson, J.
Seeger, J.
Cescon, T.
Raymond, J. M.
Geyer, C. E.
Wolmark, N.
Swain, S. M.
机构：
[1] Walter Reed Army Med Ctr, Washington, DC 20307 USA
[2] NSABP, Pittsburgh, PA USA
[3] Norton Hlth Care, Louisville, KY USA
[4] Berks Hematol & Oncol Associates, Reading, PA USA
[5] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA
[6] NCI, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1059
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II clinical trial of ZD1839 (Iressa™) in combination with docetaxel as first-line treatment in patients with advanced breast cancer
    Sheri K. Dennison
    Samuel A. Jacobs
    John W. Wilson
    Janell Seeger
    Terrence P. Cescon
    Jane M. Raymond
    Charles E. Geyer
    Norman Wolmark
    Sandra M. Swain
    Investigational New Drugs, 2007, 25 : 545 - 551
  • [2] A phase II clinical trial of ZD1839 (Iressa™) in combination with docetaxel as first-line treatment in patients with advanced breast cancer
    Dennison, Sheri K.
    Jacobs, Samuel A.
    Wilson, John W.
    Seeger, Janell
    Cescon, Terrence P.
    Raymond, Jane M.
    Geyer, Charles E.
    Wolmark, Norman
    Swain, Sandra M.
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (06) : 545 - 551
  • [3] Paclitaxel, carboplatin and gefitinib ('Iressa', ZD1839) as first-line chemotherapy in patients with advanced breast cancer: a phase II study
    Founizilas, G
    Pectasides, D
    Skarlos, DV
    Kalofonos, H
    Papadimitriou, C
    Linardou, H
    Kalogera-Fountzila, A
    Saridaki, Z
    Briassoulis, E
    Papadopoulos, S
    Lambropoulos, S
    Kosmidis, P
    Razis, E
    Gogas, H
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S85 - S85
  • [4] A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer
    Blaszkowsky, L. S.
    Ryan, D. P.
    Earle, C.
    Kwak, E.
    Fuchs, C.
    Meyerhardt, J. A.
    Stuart, K.
    Zhu, A. X.
    Enzinger, P.
    Kulke, M. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] A Phase II study of gefitinib combined with docetaxel as first-line treatment in patients with advanced breast cancer.
    Ciardiello, F
    Troiani, T
    Caputo, F
    De Laurentiis, M
    Palmieri, G
    Marinelli, A
    Colantuoni, G
    Diadema, MR
    De Placido, S
    Bianco, AR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 58S - 58S
  • [6] Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
    Ciardiello, F.
    Troiani, T.
    Caputo, F.
    De Laurentiis, M.
    Tortora, G.
    Palmieri, G.
    De Vita, F.
    Diadema, M. R.
    Orditura, M.
    Colantuoni, G.
    Gridelli, C.
    Catalano, G.
    De Placido, S.
    Bianco, A. R.
    BRITISH JOURNAL OF CANCER, 2006, 94 (11) : 1604 - 1609
  • [7] Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
    F Ciardiello
    T Troiani
    F Caputo
    M De Laurentiis
    G Tortora
    G Palmieri
    F De Vita
    M R Diadema
    M Orditura
    G Colantuoni
    C Gridelli
    G Catalano
    S De Placido
    A R Bianco
    British Journal of Cancer, 2006, 94 : 1604 - 1609
  • [8] Phase II trial of gefitinib combined with docetaxel as first-line therapy in patients with metastatic breast cancer.
    Ciardiello, F
    Troiani, T
    Caputo, F
    de Laurentiis, M
    Tortora, G
    Palmieri, G
    de Vita, F
    Colantuoni, G
    de Placido, S
    Bianco, AR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 211S - 211S
  • [9] Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib.
    Ferry, DR
    Anderson, M
    Beddows, K
    Mayer, P
    Price, L
    Jankowski, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 318S - 318S
  • [10] Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer.
    Albain, K
    Elledge, R
    Gradishar, WJ
    Hayes, DF
    Rowinsky, E
    Hudis, C
    Pusztai, L
    Tripathy, D
    Modi, S
    Rubi, S
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S33 - S33
12345